Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications
- PMID: 15521065
- DOI: 10.1002/prot.20296
Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications
Abstract
Noonan syndrome was recently reported to be caused by mutations in the PTPN11 gene in 40% of the cases. This gene encodes the nonreceptor-type protein tyrosine phosphatase SHP-2 and has been shown to be self down-regulated with the concurrency of two SH2 domains. Insertion of a specific loop (D'EF) from N-terminal SH2 domain into the SHP-2 active-site is responsible for the reversible inhibition of the phosphatase activity. Here we report the first in frame trinucleotide deletion resulting in the removal of Aspartate 61 (D61del), a key residue of the N-terminal SH2 D'EF loop. Energetic-based structural analysis and electrostatic calculations carried out on the wild-type and mutant proteins predict lower stability of the D'EF loop for the D61del variant as compared to the wild type indicating better access to the active site and most likely an enzyme activated for longer extent. Similar computations were performed on the previously functionally characterized gain-of-function D61Y mutant and similar behaviors were observed. The simulation data for the D61del and D61Y mutants suggest that both variants could yield more catalytic cycles than the wild-type molecule in the same timespan because of the opening of the active site. It also supports the notion that D61 plays a major role for proper down-regulation of the protein tyrosine phosphatase activity of SHP-2.
(c) 2004 Wiley-Liss, Inc.
Similar articles
-
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.Nat Genet. 2001 Dec;29(4):465-8. doi: 10.1038/ng772. Nat Genet. 2001. PMID: 11704759
-
PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.Hum Mutat. 2002 Oct;20(4):298-304. doi: 10.1002/humu.10129. Hum Mutat. 2002. PMID: 12325025
-
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.Cancer Res. 2004 Dec 15;64(24):8816-20. doi: 10.1158/0008-5472.CAN-04-1923. Cancer Res. 2004. PMID: 15604238
-
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.Pediatr Endocrinol Rev. 2005 Jun;2(4):669-74. Pediatr Endocrinol Rev. 2005. PMID: 16208280 Review.
-
A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail.Cell Signal. 2005 Nov;17(11):1323-32. doi: 10.1016/j.cellsig.2005.05.016. Cell Signal. 2005. PMID: 16084691 Review.
Cited by
-
Noonan Syndrome in South Africa: Clinical and Molecular Profiles.Front Genet. 2019 Apr 16;10:333. doi: 10.3389/fgene.2019.00333. eCollection 2019. Front Genet. 2019. PMID: 31057598 Free PMC article.
-
Analyzing effects of naturally occurring missense mutations.Comput Math Methods Med. 2012;2012:805827. doi: 10.1155/2012/805827. Epub 2012 Apr 22. Comput Math Methods Med. 2012. PMID: 22577471 Free PMC article.
-
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.Am J Hum Genet. 2006 Feb;78(2):279-90. doi: 10.1086/499925. Epub 2005 Dec 7. Am J Hum Genet. 2006. PMID: 16358218 Free PMC article.
-
Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.BMC Med Genet. 2020 Mar 12;21(1):50. doi: 10.1186/s12881-020-0986-5. BMC Med Genet. 2020. PMID: 32164556 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
